Holen Sie sich die Stockscreener-App
95.20
0.08%
-0.08
Handel nachbörslich:
95.20
Schlusskurs vom Vortag:
$95.28
Offen:
$95.18
24-Stunden-Volumen:
446.73K
Relative Volume:
0.45
Marktkapitalisierung:
$22.89B
Einnahmen:
$3.53B
Nettoeinkommen (Verlust:
$-632.88M
KGV:
-36.18
EPS:
-2.631
Netto-Cashflow:
$-588.37M
1W Leistung:
+0.18%
1M Leistung:
-7.71%
6M Leistung:
-10.59%
1J Leistung:
-16.45%
1-Tages-Spanne:
$94.86
$95.53
1-Wochen-Bereich:
$94.00
$95.71
52-Wochen-Spanne:
$81.20
$129.27
Biontech Se Adr Stock (BNTX) Company Profile
Vergleichen Sie BNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
95.20 | 22.91B | 3.53B | -632.88M | -588.37M | -2.631 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
Validea's Top Health Care Stocks Based On Benjamin Graham12/29/2025 - Nasdaq
Genmab–BioNTech cancer antibody trial ends early: What investors need to know - MSN
BioNTech SE Sponsored ADR $BNTX Shares Sold by TB Alternative Assets Ltd. - MarketBeat
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know - TipRanks
Vontobel Holding Ltd. Purchases 10,924 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V. - Finviz
New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech - TipRanks
BioNTech Consolidates mRNA Leadership with CureVac Acquisition Finalized () - aktiencheck.de
BMY and BNTX Advance New Immunotherapy Bet in First-Line Liver Cancer With ROSETTA HCC-206 - TipRanks
Research Analysts’ Weekly Ratings Updates for BioNTech (BNTX) - Defense World
Nanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations - GlobeNewswire Inc.
BMY and BNTX advance new immunotherapy bet in first-line liver cancer with ROSETTA HCC-206 - MSN
BioNTech's Strategic Pivot Gains Validation from Key Safety Research () - aktiencheck.de
Hudson Bay Capital Management LP Sells 15,000 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
FY2025 EPS Estimates for BioNTech Decreased by HC Wainwright - MarketBeat
Gilder Gagnon Howe & Co. LLC Has $71.08 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bellevue Group AG Raises Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
HC Wainwright Has Positive Estimate for BioNTech Q4 Earnings - Defense World
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back - Sahm
BioNTech SE’s New Study on PM8002: A Potential Game-Changer in Colorectal Cancer Treatment - MSN
Research Analysts Set Expectations for BioNTech Q4 Earnings - MarketBeat
Berenberg Bank Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street - Finviz
Invesco Ltd. Buys 35,958 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Amundi Lowers Stake in BioNTech SE Sponsored ADR $BNTX - Defense World
Altrinsic Global Advisors LLC Sells 123,995 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
ETFs investiert in BioNTech SE Sponsored ADR-AktienTradingView - TradingView - Alle Märkte im Blick
Dymon Asia Capital Singapore PTE. LTD. Makes New $1.86 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
First Trust Advisors LP Has $35.28 Million Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech's Oncology Pipeline Gains Momentum with Key Clinical Data () - aktiencheck.de
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
BioNTech Shares Gain on Promising Oncology Data and Acquisition Milestone () - aktiencheck.de
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech stock rises after promising lung cancer drug shows survival benefit By Investing.com - Investing.com South Africa
BioNTech stock rises after promising lung cancer drug shows survival benefit - Investing.com
Temasek Holdings Private Ltd Lowers Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
25,780 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Bollard Group LLC - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Dodge & Cox Invests $93.42 Million in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s (BNTX) “Buy” Rating Reaffirmed at Jefferies Financial Group - Defense World
Regulatory Storm Hits BioNTech as FDA Memo Sparks Sector-Wide Anxiety () - aktiencheck.de
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules - Nasdaq
Scotia Capital Inc. Cuts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Groupama Asset Managment Buys 26,681 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Employees Retirement System of Texas Has $1.69 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Legal & General Group Plc Boosts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Aristides Capital LLC Purchases 2,826 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE ADR Rises 3.0%, Outperforms Market - 富途牛牛
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):